COMP <GO>
CDNA vs LLY // 10Y YIELD & FRED MACRO BETA
CareDx Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CDNA 3
— LLY 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: CDNA
LAST: $87.41 (+22.22%) • MKT CAP: $3.70B
macro-sensitivity
1.06
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDNA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDNA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.20% | 32.36% | -40.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 2.30% | -1.63 | LLY | /fcf-yield <GO> |
| Operating Margin | -8.10% | 40.21% | -48.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 31.90% | -37.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 45.51% | -31.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.22 | 9.29 | +9.93 | CDNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 66.6 | -11.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.06 | 0.51 | +0.55 | CDNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 30.6x | -9.62 | CDNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.70B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDNA REV | LLY REV | CDNA GROSS % | LLY GROSS % | CDNA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | $65.18B | — | 83.0% | $24.9M | $16.81B |
| FY 2024 | $333.8M | $45.04B | — | 81.3% | $23.0M | $8.82B |
| FY 2023 | $280.3M | $34.12B | — | 79.3% | -$31.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDNA // BETA 1.06
LLY // BETA 0.51